Bio-Path Holdings Inc (NASDAQ: BPTH) is rocketing in the market this morning, more than doubling in value. The gains come on the heals of a press release, announcing that the company will be presenting data relatively soon. Today, we’ll talk about:
- The announcement;
- what we’re seeing from BPTH stock as a result; and
- what we’ll be watching for ahead.
BPTH Announces Coming Presentation
As mentioned above, Bio-Path Holdings is having a strong start to the trading session this morning. The gains come after the company issued a press release late yesterday.
In the release, the company announced that it would be offering up a presentation soon. The presentation will be provided by BPTH at the 2019 American Association for Cancer Research (AACR) Annual Meeting. AACR 2019 is set to take place between March 29, 2019 and April 3, 2019.
The presentation that BPTH will be giving will take place on April 3, 2019 between 8:00 am and noon eastern time. The presentation will be titled “BP1003, A Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor.”
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. In the case of Bio-Path, the news proved to be overwhelmingly positive. After all, the coming presentation means that we will get a good look at data as will high end investors, potential partners and more. Moreover, the company will have the opportunity to hold private meetings with key players during the event.
Considering this, it’s not surprising to see that the stock is making a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:09), BPTH is trading at $5.22 per share after a gain of $2.62 per share or 100.77% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BPTH. In particular, we’re interested in following the story surrounding the company’s continued work to use DNA powered medicine to solve some of the toughest problems in cancer care. Nonetheless, we’ll continue to follow the stock closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!